From Cancer to Autoimmunity: How CAR T Cell Therapy Is Being Repurposed

The Patient Story: A Glimmer of Hope

At 49 years old, Jan Janisch-Hanzlik found her world shrinking as multiple sclerosis (MS) tightened its grip. Once an active nurse, she was forced into a desk role. The fear of falling grew so intense that she hesitated to hold her own grandchildren. To accommodate a wheelchair she dreaded needing full-time, she moved into a larger home. Despite the best available medications, her symptoms only worsened.

That's when she heard about a clinical trial at the University of Nebraska Medical Center in Omaha, just a short drive from her home in Blair. Determined, Janisch-Hanzlik called the clinic every other month until she was accepted as the first patient in a study exploring CAR T cell therapy for autoimmune disease.

What Is CAR T Cell Therapy?

Originally developed to fight blood cancers like leukemia and lymphoma, CAR T cell therapy involves extracting a patient's own immune cells, reprogramming them in a lab to recognize and attack cancer cells, and reinfusing them into the body. These engineered cells—called chimeric antigen receptor T cells—act as living drugs, hunting down malignancies with remarkable precision.

The success of this approach in oncology has been nothing short of revolutionary. For many patients with relapsed or refractory blood cancers, CAR T therapy has meant the difference between life and death.

Expanding the Horizon: Autoimmune Diseases

Now, researchers are asking a bold question: Could the same strategy work for autoimmune conditions, where the immune system mistakenly attacks healthy tissues? Hundreds of clinical trials are underway, targeting diseases such as multiple sclerosis, lupus, Graves' disease, vasculitis, and more.

The idea is to deploy CAR T cells to hunt down and eliminate the rogue immune cells responsible for self-attack. By removing these harmful cells, the therapy could reset the immune system to a state akin to before the disease began—effectively giving patients a fresh start.

How It Differs from Cancer Treatment

In cancer, CAR T cells are designed to recognize unique markers on tumor cells. For autoimmune diseases, scientists are engineering them to target markers on autoreactive B cells or T cells. This precise targeting aims to spare the rest of the immune system, reducing side effects while halting disease progression.

Early Results and Challenges

While still experimental, early data from these autoimmune trials are encouraging. Some patients have shown sustained improvement, even after a single infusion. For Janisch-Hanzlik, the therapy offered a chance to regain control over her life—though long-term outcomes remain under study.

Nevertheless, challenges persist. The therapy is complex and expensive, and not all patients respond. There are risks of cytokine release syndrome and neurological effects, similar to those seen in cancer patients. Moreover, the durability of the immune reset is unknown—could the disease return months or years later?

What This Means for Patients

For the millions living with autoimmune diseases, the prospect of a therapy that goes beyond symptom management to actually cure the root cause is transformative. Current treatments often suppress the entire immune system, leaving patients vulnerable to infections. CAR T therapy could offer a targeted, potentially one-time fix.

Janisch-Hanzlik's story is just one of many beginning to unfold. As clinical trials expand, researchers hope to refine the approach, lower costs, and eventually make this revolutionary treatment accessible to a wider population.

To learn more about ongoing trials and eligibility, patients can consult their healthcare provider or visit clinicaltrials.gov.

• Key takeaway: CAR T cell therapy, originally a cancer treatment, is now being tested for autoimmune diseases like MS and lupus.
• Mechanism: Reprogrammed immune cells target and eliminate self-attacking cells, potentially resetting the immune system.
• Challenges: High cost, complexity, risk of side effects, and unknown long-term durability.

The road ahead is promising, but careful research remains essential.